Anaesthetic drugs & techniques
Association of esketamine exposure with secondary sclerosing cholangitis in critically ill patients: a retrospective cohort analysis of 20,000 ICU cases
Main finding · Esketamine exposure and SSC-CIPResult — go to the resultOdds ratio 1.021 per gramAuthors' conclusion
Esketamine exposure was associated with SSC-CIP in a dose-dependent manner
Study context
- Population
- ICU patients admitted January 2014–February 2022 at a tertiary university hospital532 with severe cholestasis
- Participants
- 20,973 patients
- Exposure
- Esketamine exposure vs no exposure
- Outcome
- SSC-CIP (secondary sclerosing cholangitis in critically ill patients)
Methodological detailssingle-centre, tertiary university hospital, multivariate logistic regression
- Single-centre
- Tertiary university hospital
- Multivariate logistic regression
Main finding
Esketamine exposure and SSC-CIP
Odds ratio
1.021 per gram
By group
As reported in the abstract
Observational data: associations, not effects.
Further findings
Other independent predictors of secondary sclerosing cholangitis in critically ill patients (SSC-CIP) (multivariate)
| Estimate | |
|---|---|
| ICU duration | OR 1.031 per day |
| COVID-19 | OR 20.6 |
SSC-CIP incidence
- Confirmed SSC-CIP
- 0.11%
- Clinical profile compatible with undiagnosed SSC-CIP
- 0.20%
- Incidence among COVID-19 ICU patients
- 3.24%
Original publication
Association of esketamine exposure with secondary sclerosing cholangitis in critically ill patients: a retrospective cohort analysis of 20,000 ICU cases. J Intensive Care. Published 8 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →